Spheroid cultures are among the most explored cellular biomaterials used in cardiovascular research, due to their improved integration of biochemical and physiological features of the heart in a defined architectural three-dimensional microenvironment when compared to monolayer cultures. To further explore the potential use of spheroid cultures for research, we engineered a novel in vitro model of the heart with vascularized cardiac spheroids (VCSs), by coculturing cardiac myocytes, endothelial cells, and fibroblasts isolated from dissociated rat neonatal hearts (aged 1-3 days) in hanging drop cultures. To evaluate the validity of VCSs in recapitulating pathophysiological processes typical of the in vivo heart, such as cardiac fibrosis, we then treated VCSs with transforming growth factor beta 1 (TGFβ1), a known profibrotic agent. Our mRNA analysis demonstrated that TGFβ1-treated VCSs present elevated levels of expression of connective tissue growth factor, fibronectin, and TGFβ1 when compared to control cultures. We demonstrated a dramatic increase in collagen deposition following TGFβ1 treatment in VCSs in the PicroSirius Red-stained sections. Doxorubicin, a renowned cardiotoxic and profibrotic agent, triggered apoptosis and disrupted vascular networks in VCSs. Taken together, our findings demonstrate that VCSs are a valid model for the study of the mechanisms involved in cardiac fibrosis, with the potential to be used to investigate novel mechanisms and therapeutics for treating and preventing cardiac fibrosis in vitro.

1.
Banerjee, I., J.W. Fuseler, R.L. Price, T.K. Borg, T.A. Baudino (2007) Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 293: H1883-H1891.
2.
Beauchamp, P., W. Moritz, J.M. Kelm, N.D. Ullrich, I. Agarkova, B.D. Anson, T.M. Suter, C. Zuppinger (2015) Development and characterization of a scaffold-free 3D spheroid model of induced pluripotent stem cell-derived human cardiomyocytes. Tissue Eng Part C Methods 21: 852-861.
3.
Brown, R.D., S.K. Ambler, M.D. Mitchell, C.S. Long (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45: 657-687.
4.
Bubb, K.J., C. Kok, O. Tang, N.B. Rasko, A.B. Birgisdottir, T. Hansen, R. Ritchie, R. Bhindi, S.A. Reisman, C. Meyer, K. Ward, K. Karimi Galougahi, G.A. Figtree (2017) The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling. Free Radic Biol Med 108: 585-594.
5.
Bujak, M., G. Ren, H.J. Kweon, M. Dobaczewski, A. Reddy, G. Taffet, X.F. Wang, N.G. Frangogiannis (2007) Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 116: 2127-2138.
6.
Burgoyne, J.R., H. Mongue-Din, P. Eaton, A.M. Shah (2012) Redox signaling in cardiac physiology and pathology. Circ Res 111: 1091-1106.
7.
Camelliti, P., T.K. Borg, P. Kohl (2005) Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 65: 40-51.
8.
Cartledge, J.E., C. Kane, P. Dias, M. Tesfom, L. Clarke, B. Mckee, S. Al Ayoubi, A. Chester, M.H. Yacoub, P. Camelliti, C.M. Terracciano (2015) Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovasc Res 105: 260-270.
9.
Caspi, O., A. Lesman, Y. Basevitch, A. Gepstein, G. Arbel, I.H. Habib, L. Gepstein, S. Levenberg (2007) Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circ Res 100: 263-272.
10.
Chen, W., N.G. Frangogiannis (2010) The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart Fail Rev 15: 415-422.
11.
Dobaczewski, M., M. Bujak, N. Li, C. Gonzalez-Quesada, L.H. Mendoza, X.F. Wang, N.G. Frangogiannis (2010) Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res 107: 418-428.
12.
Dobaczewski, M., W. Chen, N.G. Frangogiannis (2011) Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 51: 600-606.
13.
Eckes, J., O. Schmah, J.W. Siebers, U. Groh, S. Zschiedrich, B. Rautenberg, A. Hasenburg, M. Jansen, M.J. Hug, K. Winkler, G. Putz (2011) Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial). BMC Cancer 11: 337.
14.
Ellmers, L.J., N.J. Scott, J. Piuhola, N. Maeda, O. Smithies, C.M. Frampton, A.M. Richards, V.A. Cameron (2007) Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol 38: 245-257.
15.
Fleming, P.A., W.S. Argraves, C. Gentile, A. Neagu, G. Forgacs, C.J. Drake (2010) Fusion of uniluminal vascular spheroids: a model for assembly of blood vessels. Dev Dyn 239: 398-406.
16.
Fullerton, M.J., J.W. Funder (1994) Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 28: 1863-1867.
17.
Garzoni, L.R., D. Adesse, M.J. Soares, M.I. Rossi, R. Borojevic, N. De Meirelles Mde (2008) Fibrosis and hypertrophy induced by Trypanosoma cruzi in a three-dimensional cardiomyocyte-culture system. J Infect Dis 197: 906-915.
18.
Gentile, C. (2016) Filling the gaps between the in vivo and in vitro microenvironment: engineering of spheroids for stem cell technology. Curr Stem Cell Res Ther 11: 652-665.
19.
Gentile, C., P.A. Fleming, V. Mironov, K.M. Argraves, W.S. Argraves, C.J. Drake (2008) VEGF-mediated fusion in the generation of uniluminal vascular spheroids. Dev Dyn 237: 2918-2925.
20.
Hester, R.E., R.M. Harrison, M. Balls (2006) Alternatives to Animal Testing. Cambridge, Royal Society of Chemistry.
21.
Kelm, J.M., E. Ehler, L.K. Nielsen, S. Schlatter, J.C. Perriard, M. Fussenegger (2004) Design of artificial myocardial microtissues. Tissue Eng 10: 201-214.
22.
Lijnen, P.J., V.V. Petrov, R.H. Fagard (2000) Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 71: 418-435.
23.
Noguchi, R., K. Nakayama, M. Itoh, K. Kamohara, K. Furukawa, J. Oyama, K. Node, S. Morita (2016) Development of a three-dimensional pre-vascularized scaffold-free contractile cardiac patch for treating heart disease. J Heart Lung Transplant 35: 137-145.
24.
Ottaviano, F.G., K.O. Yee (2011) Communication signals between cardiac fibroblasts and cardiac myocytes. J Cardiovasc Pharmacol 57: 513-521.
25.
Pinto, A.R., A. Ilinykh, M.J. Ivey, J.T. Kuwabara, M.L. D'Antoni, R. Debuque, A. Chandran, L. Wang, K. Arora, N.A. Rosenthal, M.D. Tallquist (2016) Revisiting cardiac cellular composition. Circ Res 118: 400-409.
26.
Ravenscroft, S.M., A. Pointon, A.W. Williams, M.J. Cross, J.E. Sidaway (2016) Cardiac non-myocyte cells show enhanced pharmacological function suggestive of contractile maturity in stem cell derived cardiomyocyte microtissues. Toxicol Sci 152: 99-112.
27.
Rother, J., C. Richter, L. Turco, F. Knoch, I. Mey, S. Luther, A. Janshoff, E. Bodenschatz, M. Tarantola (2015) Crosstalk of cardiomyocytes and fibroblasts in co-cultures. Open Biol 5: 150038.
28.
Singla, D.K. (2015) Akt-mTOR pathway inhibits apoptosis and fibrosis in doxorubicin-induced cardiotoxicity following embryonic stem cell transplantation. Cell Transplant 24: 1031-1042.
29.
Stevens, K.R., K.L. Kreutziger, S.K. Dupras, F.S. Korte, M. Regnier, V. Muskheli, M.B. Nourse, K. Bendixen, H. Reinecke, C.E. Murry (2009) Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci USA 106: 16568-16573.
30.
Sung, K.E., X. Su, E. Berthier, C. Pehlke, A. Friedl, D.J. Beebe (2013) Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models. PLoS One 8: e76373.
31.
Sweat, F., H. Puchtler, S.I. Rosenthal (1964) Sirius Red F3ba as a stain for connective tissue. Arch Pathol 78: 69-72.
32.
Travers, J.G., F.A. Kamal, J. Robbins, K.E. Yutzey, B.C. Blaxall (2016) Cardiac fibrosis: the fibroblast awakens. Circ Res 118: 1021-1040.
33.
Tulloch, N.L., V. Muskheli, M.V. Razumova, F.S. Korte, M. Regnier, K.D. Hauch, L. Pabon, H. Reinecke, C.E. Murry (2011) Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 109: 47-59.
34.
Walkin, L., S.E. Herrick, A. Summers, P.E. Brenchley, C.M. Hoff, R. Korstanje, P.J. Margetts (2013) The role of mouse strain differences in the susceptibility to fibrosis: a systematic review. Fibrogenesis Tissue Repair 6: 18.
35.
Weber, K.T., Y. Sun, S.K. Bhattacharya, R.A. Ahokas, I.C. Gerling (2013) Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 10: 15-26.
36.
Whittaker, P., R.A. Kloner, D.R. Boughner, J.G. Pickering (1994) Quantitative assessment of myocardial collagen with PicroSirius Red staining and circularly polarized light. Basic Res Cardiol 89: 397-410.
37.
Wilkinson, P.M., G.E. Mawer (1974) The persistence of adriamycin in man and rat. Br J Clin Pharmacol 1: 241-247.
38.
Zhao, H., X. Li, S. Zhao, Y. Zeng, L. Zhao, H. Ding, W. Sun, Y. Du (2014) Microengineered in vitro model of cardiac fibrosis through modulating myofibroblast mechanotransduction. Biofabrication 6: 045009.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.